Multiple Myeloma Foundation
Multiple Myeloma (MM) is a clonal plasma cell malignancy. The CRAB criteria remain the definitive clinical guidelines for identifying symptomatic disease requiring systemic therapy.
Calcium
Hypercalcemia from bone lysis.
Renal
Insufficiency from M-protein burden.
Anemia
Low Hgb due to marrow crowding.
Bone
Lytic lesions and skeletal fractures.
Firstline Treatment & Mechanisms
Induction therapy for newly diagnosed patients utilizes distinct biological pathways. Below is the critical difference between the intracellular proteasome targeting and extracellular CD38 targeting.
Bortezomib
Mechanism: Inhibits the 26S proteasome trash-disposal system. High antibody production in plasma cells leads to toxic protein buildup, triggering apoptosis from within.
Daratumumab
Mechanism: Binds surface CD38. Acts as an immune beacon, recruiting NK cells and Macrophages to lyse the myeloma cell via ADCC.
Lenalidomide
Targets Cereblon (CRBN) to degrade survival transcription factors. Foundation of maintenance care.
Dexamethasone
Potentiates cell death across classes by suppressing inflammatory marrow signaling.
Defining RRMM
Relapsed/Refractory (RRMM) describes disease return or progression while on treatment. DREAMM-7 addresses patients reaching 1st relapse who are often refractory to frontline Lenalidomide and CD38 targeting.
RRMM Therapeutic Journey
Standard of care evolution from non-specific alkylators to high-potency targeted ADCs.
Cytotoxic Era
MP was the primary option. Median survival was limited to ~3 years.
The Triplet Shift
PIs (Bortezomib) and IMiDs transformed relapsed outcomes.
CD38 Dominance
DVd (CASTOR) and DRd (POLLUX) established the global 2nd-line standard.
DREAMM-7 Landmark
BVd tripling PFS vs Daratumumab standard in early relapse.
Spotlight: Belantamab Mafodotin (ADC)
First-in-class Antibody-Drug Conjugate (ADC) targeting BCMA.
Targeting: Antibody binds specifically to BCMA on the cell surface.
Cytotoxicity: Internalized ADC releases mafodotin to disrupt microtubules.
Role in DREAMM-7
By targeting BCMA instead of CD38, it bypasses the immune escape seen in patients failing 1L CD38-monoclonal antibodies.
Trial Evidence Dashboard
Clinical Endpoint Definitions
Progression-Free Survival
Definition: Time from starting treatment until disease progresses or patient dies.
📌 How long can we keep the cancer from getting worse?
Overall Response Rate
Definition: % of patients who achieve ≥ Partial Response (PR).
Includes:
- Partial Response (PR)
- Complete Response (CR)
📌 How many patients actually respond to the drug?
Complete Response
Definition: No detectable disease using standard clinical tests.
In multiple myeloma:
- No M-protein in blood/urine
- Normal bone marrow (no clonal plasma cells)
📌 We can't see the cancer anymore with routine testing
Minimal Residual Disease Negative
Definition: No detectable cancer cells using very sensitive testing (flow cytometry or sequencing).
Sensitivity: Detects down to 1 cancer cell in 100,000 cells (10⁻⁵).
📌 Even microscopic disease is gone
Median PFS (Months)
Response Depth (%)
Grade 3/4 Adverse Events (%)
Ocular Safety Profile
What is MECs?
Microcyst-like Epithelial Changes,tiny cyst-like inclusions in the corneal epithelium that scatter light, causing visual haziness or blur. These form due to corneal cell "micropinocytosis" (accidental sipping) of the ADC from blood.
Patient Symptoms
- Blurred Vision (most common)
- Dry Eye (grittiness sensation)
- Photophobia (light sensitivity)
- Decreased Visual Acuity (line loss on eye chart)
DREAMM-7 Outcomes
Any Grade: 60–70% of patients
Grade 3/4: 34% of patients
Resolution Rate: 98% returned to baseline
Median Time: ~22 days with dose management
Management Strategy
Fully reversible. Managed via dose delays (cycle skip) or reductions, not permanent discontinuation. Preservative-free artificial tears + ophthalmologist exams before every dose.
The Clinical Verdict
Redefining the ceiling for RRMM care via early BCMA targeting.
Regimen Scorecard
Targeted Durability
Nearly triples median PFS vs Daratumumab standard.
Response Quality
Highest MRD-negativity rate ever reported in the 2nd line triplet setting.
Community Ready
Off-the-shelf ADC brings BCMA potency to community clinics.
The New Benchmark in Early Relapse RRMM.
Effective management of ocular toxicity unlocks unprecedented disease control.